Found: 16
Select item for more details and to access through your institution.
Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 4, p. 236, doi. 10.1016/j.clml.2021.09.021
- By:
- Publication type:
- Article
Safety of the Anti-CD19 antibody Tafasitamab in Long Term Responders from A Phase II Trial for Relapsed Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 4, p. 270, doi. 10.1016/j.clml.2021.10.005
- By:
- Publication type:
- Article
Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 4, p. 260, doi. 10.1016/j.clml.2021.09.022
- By:
- Publication type:
- Article
Outcomes of HTLV-1 Carriers with Diffuse Large B-Cell Lymphoma: A Single-Center Retrospective Matched Cohort Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 4, p. 251, doi. 10.1016/j.clml.2021.09.017
- By:
- Publication type:
- Article
Clinical Characteristics, Prognosis, and Treatment Strategies of TP53 Mutations in Myelodysplastic Syndromes.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 4, p. 224, doi. 10.1016/j.clml.2021.09.013
- By:
- Publication type:
- Article
Erratum to 'Potential New Therapeutic Approaches for Myelofibrosis' [Clinical Lymphoma Myeloma & Leukemia 21S1 (2021) S130-S133/EXABS-189-MPN].
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 4, p. 277, doi. 10.1016/j.clml.2021.12.001
- By:
- Publication type:
- Article
Corrigendum to 'MPN-395: Efficacy and Safety of ≤200 mg Avapritinib in Patients with Advanced Systemic Mastocytosis: Pooled Results from the Phase 1 EXPLORER and Interim Phase 2 PATHFINDER Studies' [Clinical Lymphoma Myeloma & Leukemia 21S1 (2021) S367-S368]
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 4, p. 276, doi. 10.1016/j.clml.2021.12.002
- By:
- Publication type:
- Article
SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 4, p. 210, doi. 10.1016/j.clml.2021.10.002
- By:
- Publication type:
- Article
Characterization of Primary and Secondary Cutaneous B-Cell Lymphomas: A Population-Based Study of 4758 Patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 4, p. e269, doi. 10.1016/j.clml.2021.10.009
- By:
- Publication type:
- Article
SOHO State of the Art Updates and Next Questions: BTK inhibitors combined with chemoimmunotherapy in CLL, the best of both worlds?
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 4, p. 205, doi. 10.1016/j.clml.2021.09.012
- By:
- Publication type:
- Article
Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 4, p. e279, doi. 10.1016/j.clml.2021.10.008
- By:
- Publication type:
- Article
CAR-T in B-Cell Lymphomas: The Past, Present, and Future.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 4, p. e261, doi. 10.1016/j.clml.2021.10.003
- By:
- Publication type:
- Article
Characteristics and Outcome of Extranodal NK/T-Cell Lymphoma in North America: A Retrospective Multi-Institutional Experience.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 4, p. e250, doi. 10.1016/j.clml.2021.10.004
- By:
- Publication type:
- Article
Clinical and Sociodemographic Characteristics of Patients With Relapsed and/or Refractory Multiple Myeloma and Their influence on Treatment in the Real-World Setting in Spain: The CharisMMa Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 4, p. e241, doi. 10.1016/j.clml.2021.10.001
- By:
- Publication type:
- Article
Secondary Acute Myeloid Leukemia (sAML): Similarly Dismal Outcomes of AML After an Antecedent Hematologic Disorder and Therapy Related AML.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 4, p. e233, doi. 10.1016/j.clml.2021.09.019
- By:
- Publication type:
- Article
Prevalence and Clinical Outcome of FMS -Like Tyrosine Kinase Mutations Among Patients With Core Binding Factor--Acute Myeloid Leukemia: Systematic Review and Meta-Analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 4, p. e221, doi. 10.1016/j.clml.2021.09.020
- By:
- Publication type:
- Article